Granules’ generic anticholinergic drug gets U.S. FDA nod
The Hindu
Granules India's Glycopyrrolate Oral Solution approved by U.S. FDA for paediatric patients with neurological conditions.
Drugmaker Granules has received U.S. Food and Drug Administration (U.S. FDA) approval for its abbreviated new drug application (ANDA) for Glycopyrrolate Oral Solution 1mg/5mL.
The approved product will be bioequivalent and therapeutically equivalent to the reference listed drug Merz Pharmaceuticals LLC’s Cuvposa Oral Solution1 mg/5 mL, Granules India said in a release on the U.S. FDA nod for subsidiary Granules Pharmaceuticals Inc. (GPI) ANDA.
Glycopyrrolate Oral Solution is an anticholinergic medication indicated for paediatric patients aged 3-16 years who have neurological conditions associated with problem drooling. “As we strengthen Granules’ footprint in the U.S. market, this approval highlights our robust quality systems, ensuring compliance with the highest regulatory standards,” said Granules India CMD Krishna Prasad Chigurupati said.
Granules India shares closed 1.77% higher at ₹.673.95 each on the BSE.
Silver futures soar to ₹2.32 lakh/kg as global prices exceed $75, marking a record high in commodities trading.
Stock markets decline as Sensex and Nifty fall amid foreign fund outflows and low trading volumes on December 26, 2025.
Rupee drops 23 paise to 89.94 against the dollar amid negative equity trends and rising crude prices.
The commencement of commercial flight from the Navi Mumbai International Airport (NMIA) is expected to speed up infrastructure and real estate development across Navi Mumbai and surrounding regions, analysts & industry executives said.
GCCs keep India’s tech job market alive, even as IT services industry embarks on a hiring moratorium
Global Capability Centres, offshore subsidiaries set up by multinational corporations, mostly known by an acronym GCCs, are now the primary engine sustaining India’s tech job market, contrasting sharply with the hiring slowdown witnessed by large firms in the country.
India’s manufacturing sector underperforms compared to China and South Korea, partly due to public sector wages that raise costs and reduce competitiveness.
Non-Resident Indians (NRIs) from the Gulf Cooperation Council (GCC) region, once prominent investors in the Indian equity market are seen shying away due to rupee depreciation and have moved to global funds, said a top financial services executive.
Mobile phones are increasingly migrating to smaller chips that are more energy efficient and powerful supported by specialised Neural Processing Units (NPUs) to accelerate AI workloads directly on devices, said Anku Jain, India Managing Director for MediaTek, a Taiwanese fabless semiconductor firm that claims a 47% market share India’s smartphone chipset market.
In one more instance of a wholly owned subsidiary of a Chinese multinational company in India getting ‘Indianised’, Bharti Enterprises, a diversified business conglomerate with interests in telecom, real estate, financial services and food processing among others, and the local arm of private equity major Warburg Pincus have announced to collectively own a 49% stake in Haier India, a subsidiary of the Haier Group which is headquartered in Qingdao, Shandong, China.
Indian stock markets closed lower amid volatility, with key firms lagging as global trends influenced trading activity.
Bharti and Warburg Pincus invest in Haier India, acquiring a 49% stake to enhance growth and innovation in consumer durables.
India's net FDI remains negative for October 2025, with outflows surpassing inflows amid trade deal uncertainties.
Bombay High Court halts fraud notices to Anil Ambani, questioning banks' compliance and the audit's validity.